| Old Articles: <Older 4751-4760 Newer> |
|---|
 |
Reason
April 2008
Ronald Bailey |
Medical Speech As a 1997 law expires, the FDA is mulling a plan allowing companies to disseminate unabridged reprints of "truthful and non-misleading" medical journal articles describing "off-label" uses of approved medications to physicians.   |
The Motley Fool
April 10, 2008
Brian Lawler |
Nektar Can't Squeeze Nectar From This Drug Nektar Therapeutics announced that it was putting its inhaled insulin drug, Exubera, to rest. Investors, take note. |
The Motley Fool
April 10, 2008
Brian Lawler |
Glaxo Angers the FDA GlaxoSmithKline announces that the FDA has sent it a warning letter regarding its failure to meet certain post-marketing requirements for Avandia. |
The Motley Fool
April 10, 2008
Brian Orelli |
The News for Baxter Just Got Worse These heparin-related deaths aren't associated with Baxter's product, but they still might spell trouble for the company. |
Chemistry World
April 9, 2008
Mark Peplow |
vCJD filter for blood could be in use 'by summer' ProMetic's prion filter, attached to a blood pack, is being marketed by French medical equipment company MacoPharma to clean blood of the proteins responsible for variant Creutzfeldt-Jakob disease (vCJD). |
The Motley Fool
April 9, 2008
Brian Orelli |
Isis Ignited by Bristol-Myers Bristol-Myers Squibb selects an Isis-developed compound, triggering a milestone payment. |
The Motley Fool
April 9, 2008
Brian Orelli |
Repligen Gets a Surprise Infusion of Cash Bristol-Myers Squibb agrees to pay Repligen royalties in their patent-infringement lawsuit. |
The Motley Fool
April 9, 2008
Brian Orelli |
Russia Approves an Unproven Treatment Antigenics gains approval of Oncophage in Russia, making it the first pharmaceutical to gain approval of any cancer vaccine. |
The Motley Fool
April 8, 2008
Brian Lawler |
FDA Approvals ... Increase? So far in 2008, the agency has given more drugs a thumbs-up than this time in 2007. Take a look at which companies received approvals. |
The Motley Fool
April 8, 2008
Brian Orelli |
Songs of the One-Drug Wonders Will these companies become big-name drugmakers or get lost in history? Let's take a quick look at: Abraxis Bioscience... Elan... Amylin Pharmaceuticals... Onyx Pharmaceuticals... |
| <Older 4751-4760 Newer> Return to current articles. |
